Short answer
Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Election of Directors or Officers). Board expanded to nine directors, adding Craig Tendler as an independent Class II director through the 2028 annual meeting.
Parabilis Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to nine directors, adding Craig Tendler as an independent Class II director through the 2028 annual meeting
- Tendler joins the Science & Technology Committee, strengthening board-level scientific oversight
- Equity award: option for 20,294 shares at $39.36 exercise price, vesting monthly over three years
- Annual compensation: $40,000 Board retainer plus $7,500 Science & Technology Committee retainer
- No disclosed related-party transactions or selection arrangements, reducing governance conflict concerns
Item 7.01 · Regulation FD Disclosure
- Tendler appointed to Parabilis Medicines’ Board, adding a new director to the company’s governance structure
- Appointment announcement dated August 25, 2026, with investor relevance dependent on Tendler’s background and board role
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Parabilis Medicines Inc 8-K filings
Get the next PBLS 8-K as it lands
Follow PBLS for push alerts, or ask the research agent what this filing means.